| Diffuse Large B-Cell Lymphoma Unclassifiable studied in …STUDIED_INderived17 of 17show fewer |
|---|
| → studied in | NCT06649812Phase 2 · recruiting Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma · condition mapped CURATED_BROADER · 17 trials mapped (11 active) | — | — | Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05627245Phase 1 · active not recruiting Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment · condition mapped CURATED_BROADER · 17 trials mapped (11 active) | — | — | Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04665765Phase 2 · active not recruiting Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 17 trials mapped (11 active) | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05294731Phase 1/Phase 2 · recruiting Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader · condition mapped ALIAS · 17 trials mapped (11 active) | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03656835NA · active not recruiting Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 17 trials mapped (11 active) | — | — | Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04799275Phase 2/Phase 3 · active not recruiting Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 17 trials mapped (11 active) | — | — | Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03038672Phase 2 · active not recruiting Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas · condition mapped ONTOLOGY_EXACT · 17 trials mapped (11 active) | — | — | Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05755087Phase 1 · recruiting Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 17 trials mapped (11 active) | — | — | Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04512716early Phase 1 · recruiting Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma · condition mapped ALIAS · 17 trials mapped (11 active) | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05544019Phase 1 · recruiting Study of SGR-1505 in Mature B-Cell Neoplasms · condition mapped ALIAS · 17 trials mapped (11 active) | — | — | Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06834373Phase 2 · recruiting Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy · condition mapped CURATED_BROADER · 17 trials mapped (11 active) | — | — | Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03742258Phase 1 · completed Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 17 trials mapped (11 active) | — | — | Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04933617Phase 1 · terminated Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas · condition mapped ALIAS · 17 trials mapped (11 active) | — | — | Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05422066Phase 2 · unknown Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma · condition mapped ALIAS · 17 trials mapped (11 active) | — | — | Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02636322Phase 2 · completed Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib · condition mapped ONTOLOGY_EXACT · 17 trials mapped (11 active) | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02134782NA · terminated Yoga Fatigue Study · condition mapped ALIAS · 17 trials mapped (11 active) | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03704714Phase 1/Phase 2 · suspended Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 17 trials mapped (11 active) | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 1 | Observed | clinicaltrials | graph → |